Premenstrual Syndrome Treatment Market to 2026 Increasing Demand with Leading Key Players ABBVIE INC.,AstraZeneca Plc. ,BASF Corporation
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026.
View full press release